Table 5.
Adverse events reported in published studiesa during or after rituximab-induced B-cell depletion therapy
| Infections | Pneumoniab |
| Shinglesb | |
| Thigh abscess, subcutaneous abscess | |
| Urinary tract infection | |
| Septicaemia | |
| Psuedomonas infection | |
| Staphyloccal abscess | |
| Streptococcal viridans infection | |
| Necrotising fasciitis | |
| Fatal histoplasmosis | |
| Haematological | Neutropeniab |
| Pulmonary | Pneumonia |
| Pulmonary haemorrhage | |
| Pulmonary embolism | |
| Respiratory failurec | |
| Breathlessness | |
| Cardiac | Cardiac failurec |
| Fatal pancarditisc | |
| Pericarditis | |
| Tachycardia | |
| Neurological | Insomnia |
| Transient ischaemic attack | |
| Skin | Localised or widespread rashb |
| Pruritis | |
| Urticaria | |
| Miscellaneous | Infusion reactionsb |
| Serum sickness reaction | |
| Hypogammaglobulinaemia | |
| Anaphylaxis | |
| Deep vein thrombosis | |
| Dyspepsia | |
| Malaise | |
| Pyrexia | |
| Polyarthralgia |
aSee Table 1. bFrequently reported adverse event. cLife-threatening complications.